GUANOSINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H13N5O5
Molecular Weight	283.2407
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

NC1=NC2=C(N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C(=O)N1

InChI

InChIKey=NYHBQMYGNKIUIF-UUOKFMHZSA-N

InChI=1S/C10H13N5O5/c11-10-13-7-4(8(19)14-10)12-2-15(7)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,19)/t3-,5-,6-,9-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C10H13N5O5
Molecular Weight	283.2407
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

Guanosine is an endogenous guanine nucleoside. Guanosine was shown to be protective in several in vitro and/or in vivo experimental models of central nervous system (CNS) diseases including ischemic stroke, Alzheimer's disease, Parkinson's disease, spinal cord injury, nociception, and depression. The mechanisms underlying the neurobiological properties of guanosine seem to involve the activation of several intracellular signaling pathways and a close interaction with the adenosinergic system, with a consequent stimulation of neuroprotective and regenerative processes in the CNS. Several guanosine analogues, i.e. acyclovir (and its oral prodrug valaciclovir), penciclovir (in its oral prodrug form, famciclovir) and ganciclovir, are widely used for the treatment of herpesvirus (i.e. HSV-1, HSV-2, VZV and HCMV) infections.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
apoptotic process 48	Inhibitor 8,297
Oxidative Stress 160	Inhibitor 8,297
cell proliferation 28	Activator 1,430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Stroke 144	Primary		Preclinical	Unknown
Hepatic encephalopathy 5	Primary		Preclinical	Unknown

PubMed

Show entries

Title	Date	PubMed
Constitutive activity at serotonin 5-HT(1D) receptors: detection by homologous GTPgammaS versus [(35)S]-GTPgammaS binding isotherms.	2001	11077071
Modulation of 5-HT(1A) receptor activation by its interaction with wild-type and mutant g(alphai3) proteins.	2001	11077069
Ca2+-induced contraction of cat esophageal circular smooth muscle cells.	2001 Apr	11245615
CB1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains.	2001 Feb	11168387
A novel proton-dependent nucleoside transporter, CeCNT3, from Caenorhabditis elegans.	2001 Feb	11160871

Showing 1 to 5 of 15 entries

Previous1 2 3Next

Sample Use Guides

In Vivo Use Guide

rat model of chronic hepatic encephalopathy: i.p. injection of guanosine 7.5 mg/kg once a day for 1-week.

Route of Administration: Other

In Vitro Use Guide

Guanosine incubated concomitantly with Rot/oligo abolished Rot/oligo-induced cell death and ROS production in a human neuroblastoma cell line, SH-SY5Y, in a concentration dependent manner; maximum protection was achieved at the concentration of 1 mM.